Delivery Order SPE2DB24D2013-SPE2DB25FCHJY

Award Date 2/10/25
Potential Completion Date 2/11/25
Potential Value $31K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,471.11, is a firm-fixed-price delivery order for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has an ultimate completion date of January 29, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $21,370.80 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to manage diabetes. The contract has an ultimate completion date of November 25, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, with a ceiling value of $26,675.53, is a delivery order contract for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has an ultimate completion date of December 27, 2024 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,659.18 Firm Fixed Price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 1.5ML, a prescription medication used for diabetes management. The contract has an ultimate completion date of July 22, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,817.48 Firm Fixed Price Delivery Order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has an ultimate completion date of July 29, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,417.29, is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has a firm fixed price and an ultimate completion date of February 11, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication, with a ceiling value of $28,934.42 and a performance period through April 26, 2023. The contract was not designated as a set-aside. AmerisourceBergen is the prime contractor and holds a larger Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $11,835.66, is for the delivery of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a diabetes medication. The contract is a Firm Fixed Price Delivery Order with a completion date of December 30, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,904.63 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of November 22, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,706.99 firm-fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of January 6, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
  • SPE2DB24D2013
    Indefinite Delivery Contract
  • SPE2DB24D2013-SPE2DB25FCHJY
    Delivery Order

This is a Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication, with a ceiling value of $30,914.15 and a completion date of February 11, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies for military personnel, veterans, and other federal beneficiaries.

The contract award was not designated with any set-aside requirements, indicating open competition.

Generated 5/12/25, 10:36 AM